National Institute For Health And Care Excellence (NICE) Recommends Jardiance® (Empagliflozin) For The Treatment Of Type 2 Diabetes (T2D) To Improve Glycaemic Control In Adults

BRACKNELL, England--(BUSINESS WIRE)--The Boehringer Ingelheim and Eli Lilly Diabetes Alliance announced today that the National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Determination1 (FAD) recommending Jardiance (empagliflozin) for use within the National Health Service (NHS England) in the treatment of type 2 diabetes as follows:-

1.1 Empagliflozin in a dual therapy regimen in combination with metformin is recommended as an option for treating type 2 diabetes, only if:

• a sulfonylurea is contraindicated or not tolerated, or

Help employers find you! Check out all the jobs and post your resume.